Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 23, 2009, Pages 9379-9384

  Lakshmikanthan, Vijayabaskar ^a   Zou, Lin ^a   Kim, Jae I ^a   Michal, Allison ^b   Nie, Zhongzhen ^a   Messias, Nidia C ^a   Benovic, Jeffrey L ^b   Daaka, Yehia ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; Beta arrestin; Mdm2; Testosterone; Ubiquitin

Indexed keywords

ANDROGEN RECEPTOR; BETA ARRESTIN; BETA ARRESTIN 2; PROSTATE SPECIFIC ANTIGEN; PROTEIN MDM2; SCAFFOLD PROTEIN; TESTOSTERONE; UBIQUITIN; AR PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; RETINA S ANTIGEN;

ARTICLE; CELL NUCLEUS; COMPLEX FORMATION; CONTROLLED STUDY; CYTOSOL; EFFECTOR CELL; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROTEIN STABILITY; UBIQUITINATION;

ARRESTINS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 67249152481     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900258106     Document Type: Article

References (35)

1. Jemal A, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
2. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45. (Pubitemid 33741879)
3. Grossmann ME, Huang HJ, Tindall DJ (2001) Androgen receptor signaling in androgenrefractory prostate cancer. J Natl Cancer Inst 93:1687-1697. (Pubitemid 33130257)
4. Heinlein CA, Chang CS (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276-308. (Pubitemid 38501396)
5. Daaka Y (2004) G proteins in cancer: The prostate cancer paradigm. Sci STKE 2004:re2.
6. Bagchi G, Moniri NH, Daaka Y (2006) Androgen Receptor. Nat Signal Gateway AA003790.
7. Lara PN, et al. (1999) Molecular biology of prostate carcinogenesis. Crit Rev Oncol Hematol 32:197-208.
8. Koivisto P, et al. (1997) Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319. (Pubitemid 27036612)
9. Linja MJ, et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555. (Pubitemid 32694958)
10. Quigley CA, et al. (1995) Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr Rev 16:271-321.
11. Gioeli D, et al. (2002) Androgen receptor phosphorylation: Regulation and identification of the phosphorylation sites. J Biol Chem 277:29304-29314.
12. Fu MF, et al. (2000) p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853-20860. (Pubitemid 30457679)
13. Poukka H, et al. (2000) Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145-14150. (Pubitemid 32016544)
14. Lin HK, et al. (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21:4037-4048. (Pubitemid 34857436)
15. Moore CA, Milano SK, Benovic JL (2007) Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69:451-482. (Pubitemid 46457651)
16. Ferguson SS, et al. (1996) Role of beta-Arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363-366. (Pubitemid 3021512)
17. Shenoy SK, Lefkowitz RJ (2005) Seven-transmembrane receptor signaling through βArrestin. Science Signal 2005:cm10.
18. Goodman OB, et al. (1996) βArrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor. Nature 383:447-450. (Pubitemid 26330835)
19. Laporte SA, et al. (2000) The interaction of βArrestin with the AP-2 adaptor is required for the clustering of β2-adrenergic receptor into clathrin-coated pits. J Biol Chem 275:23120-23126. (Pubitemid 30646204)
20. Shenoy SK, et al. (2001) Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and βArrestin. Science 294:1307-1313. (Pubitemid 33063090)
21. Shenoy SK, et al. (2008) Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the β2-adrenergic receptor. J Biol Chem 283:22166-22176.
22. Xiao K, et al. (2007) Functional specialization of βArrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 104:12011-12016. (Pubitemid 47185621)
23. Kang HY, et al. (1999) Cloningandcharacterization ofhumanprostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274:8570-8576. (Pubitemid 29164648)
24. Poukka H, et al. (2000) The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci 113:2991-3001.
25. Marchese A, et al. (2008) G protein-coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol 48:601-629. (Pubitemid 351738165)
26. Gaughan L, et al. (2005) Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33:13-26. (Pubitemid 40276925)
27. Girnita L, et al. (2005) βArrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the Mdm 2 E3 ligase. J Biol Chem 280:24412-24419. (Pubitemid 40934525)
28. McLachlan RI, et al. (1996) The endocrine regulation of spermatogenesis: Independent roles for testosterone and FSH. J Endocrinol 148:1-9. (Pubitemid 26022184)
29. Spada ARL, et al. (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79. (Pubitemid 21896702)
30. Yang Z, et al. (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 13:348-353. (Pubitemid 46376683)
31. Beaulieu J-M, et al. (2005) An Akt/βArrestin2/PP2A Signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273. (Pubitemid 41032989)
32. Bagchi G, et al. (2008) Androgens transduce the Gαs-mediated activation of protein kinase A in prostate cells. Cancer Res 68:3225-3231.
33. Chen CD, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39. (Pubitemid 38524696)
34. Niu YJ, et al. (2008) Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 105:12182-12187.
35. Guo R, et al. (2006) Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147:4883-4892. (Pubitemid 44402195)